Comparison of Molecular Diagnostic Tests and Clinical Validation of CancerTYPE ID

Comparison of Molecular Diagnostic Tests and Clinical Validation of CancerTYPE ID

CancerTYPEID

4 years
612 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Dr. Boccia compares CancerTYPE ID to other gene expression tests and reviews studies validating its accuracy and clinical utility. For more information, visit: http://www.cancertypeid.com
Up Next Autoplay
Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
Category: Chronic Myelogenous Leukemia
1 Views
Cancer-News 4 hours
Perspectives on the Future of CML
Perspectives on the Future of CML
Category: Chronic Myelogenous Leukemia
0 Views
Cancer-News 4 hours
2019 Nobel Prize for Medicine Recipients recognized for Cancer Research  through study of von Hippel-Lindau (VHL) disease
2019 Nobel Prize for Medicine Recipients recognized for Cancer Research through study of von Hippel-Lindau (VHL) disease
Category: Acute Lymphoblastic Leukemia
1 Views
Cancer-News 4 hours
Re-evaluating TKI in CML Patients During Pregnancy
Re-evaluating TKI in CML Patients During Pregnancy
Category: Chronic Myelogenous Leukemia
0 Views
Cancer-News 5 hours
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
Category: Acute Myelogenous Leukemia
2 Views
Cancer-News 5 hours
CML and Pregnancy
CML and Pregnancy
Category: Chronic Myelogenous Leukemia
1 Views
Cancer-News 5 hours
INNATE PHARMA HIGHLIGHTS FDA-APPROVED LUMOXITI® AT ASH 2019
INNATE PHARMA HIGHLIGHTS FDA-APPROVED LUMOXITI® AT ASH 2019
Category: Acute Lymphoblastic Leukemia
2 Views
Cancer-News 5 hours
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refrac...
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refrac...
Category: Chronic Lymphocytic Leukemia
2 Views
Cancer-News 5 hours
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Category: Non-Hodgkin Lymphoma
3 Views
Cancer-News 6 hours
First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers
First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers
Category: News
1 Views
Cancer-News 6 hours